



OPEN ACCESS

EDITED BY

Xia Jing,
Clemson University, United States

REVIEWED BY

Seth Russell,
University of Colorado Anschutz Medical
Campus, United States
Nick Williams,
National Institutes of Health, United
States

*CORRESPONDENCE

Luca Moschetti
✉ moschetti.luca@aou.mo.it

RECEIVED 04 December 2025

REVISED 09 March 2026

ACCEPTED 12 March 2026

PUBLISHED 09 April 2026

CITATION

Moscetti L, Calanchi E, Pettorelli E, Spallanzani A, Bertolini F, Fogliani R, Orsini M, Delsante L, Civallero M, Depenni R, Di Emidio K, Gelsomino F, Fontana A, Piacentini F, Sabbatini R and Dominici M (2026) Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center.
Front. Digit. Health 8:1760649.
doi: 10.3389/fdgth.2026.1760649

COPYRIGHT

© 2026 Moschetti, Calanchi, Pettorelli, Spallanzani, Bertolini, Fogliani, Orsini, Delsante, Civallero, Depenni, Di Emidio, Gelsomino, Fontana, Piacentini, Sabbatini and Dominici. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center

Luca Moschetti^{1*}, Enrico Calanchi², Elisa Pettorelli¹, Andrea Spallanzani¹, Federica Bertolini¹, Rossella Fogliani³, Mirko Orsini², Laura Delsante², Monica Civallero^{4,5}, Roberta Depenni¹, Katia Di Emidio¹, Fabio Gelsomino¹, Annalisa Fontana¹, Federico Piacentini^{4,5}, Roberto Sabbatini¹ and Massimo Dominici^{4,5}

¹Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy, ²Datariver, Modena, Italy, ³Servizio Tecnologie dell'informazione, University Hospital of Modena, Modena, Italy, ⁴Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy, ⁵Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

Objectives: The transition from paper medical records to electronic health records (EHRs) has enabled the extraction of substantial real-world data, which can support future real-world evidence generation. This study aimed to convert heterogeneous oncology data from local EHR systems—collectively referred to as COMNet—into a standardized data model. In particular, the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) was adopted to harmonize routinely collected clinical data into a common database, thereby enabling standardized secondary use and large-scale analyses.

Methods: Demographic and clinical parameters routinely collected at the Modena Cancer Center were retrospectively extracted from COMNet and harmonized into the OMOP-CDM through an Extract–Transform–Load process supported by the European Health Data and Evidence Network (EHDEN).

Results: We identified 85,026 persons with at least one recorded condition occurrence. Discrepancies were observed across OMOP-CDM domains—particularly in visit occurrence and drug exposure—reflecting changes in documentation practices and source systems over time. The temporal trend of data migration to the electronic platform revealed two significant peaks, corresponding to initial data entry and subsequent digitalization of hospital facilities and pharmacy records.

Discussion: The harmonization process revealed data inconsistencies, including incompleteness and missing data, reflecting challenges inherent in the transition from paper-based records to electronic systems and the coexistence of different legacy software platform.

Conclusions: Harmonizing COMNet data into the OMOP-CDM produced a standardized real-world data resource that can support future observational research and participation in federated network studies. Ongoing initiatives, including the EHDEN project, are supporting the further development of COMNet to improve interoperability and enhance structured data capture.

KEYWORDS

data harmonization, electronic health records, OMOP Common Data Model, oncology, real-world data

Background

The evolution of treatments—particularly the development of targeted therapies and the advent of immunotherapy—has revolutionized therapeutic strategies for early and metastatic cancers over the past decade (1, 2). The availability of new treatments has highlighted that individual patient clinical information alone is often insufficient to define optimal treatment, necessitating the integration of anatomical, pathological, and molecular parameters obtained through advanced technologies such as gene sequencing. The effectiveness of new drugs—both as monotherapy and in combination with chemotherapy or hormone therapy—is associated with various predictive factors derived from immunohistochemical and molecular biology analyses (3). The dynamic nature of this treatment landscape, shaped by registration trials with specific patient selection criteria, underscores the need to collect real-world data (RWD) to evaluate the feasibility and outcomes of these therapies in routine outpatient clinical practice (4). The transition from paper records to electronic health records (EHRs) has facilitated access to large volumes of clinical information potentially useful for observational research. However, the secondary use of EHR data is frequently limited by data quality issues such as incompleteness, inconsistencies, and heterogeneous coding practices (5–7).

To address these challenges, we conducted a retrospective study involving the extraction of available oncology data from the Modena Cancer Center, supported by the European Health Data and Evidence Network (EHDEN), a European initiative promoting the adoption of the OMOP Common Data Model (OMOP-CDM) across sites (8). The OMOP-CDM enables federated observational research across distributed data partners (9, 10). The OMOP-CDM was utilized to convert heterogeneous data from EHR sources within the local oncology data platform (COMNet) into a standardized structure and vocabulary, creating a common database that enables the secondary use of routinely collected clinical data (11, 12). This work contributes to the existing OMOP-CDM literature by describing a real-world implementation in an academic oncology center and highlighting practical challenges related to historical EHR migrations and data quality.

Methods

This retrospective, single-center, observational cohort study included all patients with solid tumors who presented at the Modena Cancer Center from 2001 onward. The objective of the study was to create a database by collecting demographic and

clinical parameters to evaluate the outcomes of patients treated in routine clinical practice, distinct from those in clinical trials.

This database was designed to support the development of future real-world evidence studies by enabling the identification of relevant clinical parameters and providing a standardized, anonymized data platform suitable for large-scale analyses.

For included patients, retrospective data collection encompassed the following:

- Demographic information: gender, age, place of birth (referring to the municipality and country of birth as recorded in the institutional administrative systems), and ethnicity.
- Clinical data: start and end dates of therapies, dates and results of instrumental re-evaluations (i.e., imaging-based reassessments performed during follow-up, such as CT, MRI, or PET, when available in structured form).
- Histopathological and molecular diagnoses.
- Therapies: systemic and locoregional treatments.

All prevalent and incident patients diagnosed with solid tumors from 2001 onward were consecutively enrolled.

Eligibility criteria were as follows:

- Age >18 years.
- Diagnosis of solid neoplasia since 2001 (eligibility determined by the presence of an oncology diagnosis recorded in the source systems and mapped into the OMOP condition occurrence domain).
- All disease stages of solid tumors managed by oncology for surgery, subsequent therapies, or follow-up.

Data were obtained from multiple sources, including institutional administrative databases, radiological examination databases, and laboratory databases. These systems were integrated through a unified patient identification process, with each individual assigned a unique ID code. Patient records from multiple institutional systems were linked using the institutional master patient index prior to anonymization and OMOP conversion.

The IT and Telematics Technologies Service performed patient extraction queries from the various applications and ensured anonymization. DataRiver, an EHDEN-certified SME, provided support for the mapping process, Extract--Transform--Load (ETL) development, and the setup of the working environment and tools to standardize data according to the OMOP Common Data Model.

Technically, harmonization with the OMOP-CDM involved custom data extraction from the Microsoft SQL Server (MSSQL)

data source, which was imported into a dedicated PostgreSQL instance. The resulting integrated and reorganized dataset enabled a fully automated ETL process without the need for additional manual intervention.

Analysis and control tools provided by the EH DEN community allowed continuous verification of the effectiveness and consistency of the standardization process, supporting distributed studies with global data partners.

Source data profiling and ETL design were performed using the OHDSI open-source tools White Rabbit and Rabbit-in-a-Hat. White Rabbit was used to scan the COMNet source database to generate a profiling report describing tables, fields, and value distributions. Rabbit-in-a-Hat was then used to design and document the mapping logic required to transform the COMNet source fields into the OMOP-CDM target tables.

Ethical considerations

The study was conducted in accordance with Good Clinical Practice guidelines established by the International Council for Harmonization and the provisions of the Declaration of Helsinki. Approval was granted by the local ethical committee (reference number Comitato Etico dell'Area Vasta Emilia Nord, nr 180/2022, 23 November 2023). Although the study was observational, informed consent was obtained from patients who were alive and able to understand and sign a written statement of consent. This included consent to participate in drug-free clinical trials, the use of biological material for scientific purposes, and the processing of personal data, in compliance with the Privacy Law (Italian Legislative Decree No. 196/2003).

For patients who were deceased or could not be located, consent was not required, in accordance with the General Authorization to Process Personal Data for Scientific Research Purposes (1 March 2012) issued by the Guarantor for the Protection of Personal Data (published in the Official Italian Gazette No. 72, 26 March 2012). Moreover, earlier ethical approval was obtained from the same ethics committee (Comitato Etico Area Vasta Emilia Nord, reference number 001282/20, dated 15 January 2020), covering activities related to data extraction and management.

Results

A total of 89,211 persons were included in the OMOP database. Among them, 85,026 had at least one record in the condition occurrence domain and 39,230 had a defined observation period. The distribution of records across OMOP domains is summarized in Table 1.

Visit occurrence was reported in 15,923 patients a (event where persons engage with the healthcare system for a duration of time). Death was recorded for 39,677 patients. A procedure occurrence (records of activities or processes ordered by, or carried out by, a healthcare provider on the patient with a diagnostic or therapeutic purpose) was conducted in 80,167, whereas a measurement (structured values, numerical or categorical, obtained through systematic and standardized examination or testing of a person or person's sample:

laboratory tests, vital signs, and quantitative findings from pathology report) was recorded in 80,167. Drug exposure—ingested or otherwise introduced into the body—was reported in 13,998.



Discrepancies across OMOP domains (visit occurrence, drug exposure, procedure occurrence, and measurement) were observed, reflecting differences in documentation practices and source systems over time. In particular, differences in drug exposure may reflect limitations in the structured capture of oral therapies. The complete results are shown in Table 1.

Age at first observation is reported in Figure 1. The temporal trend of data migration to the electronic platform shows two significant peaks (Figure 2). The first peak occurred in the early 2000s with the entry of data related to observations and digitalization of laboratory assessment. A second peak was observed in the second decade of the 2000s, coinciding with the digitization of the hospital pharmacy (Figure 2).

The number of distinct concepts per person across OMOP domains is shown in Figure 3. The results highlight the increase in clinical data entry and digitalization over the last two decades. An increase in the use of cancer drugs was observed after 2010, reflecting the introduction of new systemic therapies, including targeted treatments and precision oncology approaches. In addition, a parallel increase in clinical instrumental controls was observed, reflected in the increased number of measurement and observation records. The limited availability of visit data prior to 2010 reflects changes in clinical documentation practices and the progressive digitalization of

TABLE 1 Number of records in all clinical data tables.

Table name	Count	N_Persons
Drug_exposure	1,288,618	13,998
Measurement	1,175,181	83,838
Observation	533,197	85,367
Condition_occurrence	299,048	85,026
Procedure_occurrence	285,436	80,167
Condition_era	275,151	85,026
Drug_era	137,140	13,994
Person	89,211	89,211
Observation_period	57,775	39,230
Visit_occurrence	46,586	15,923
Death	39,677	39,677
Specimen	0	0
Dose_era	0	0
Device_exposure	0	0
Visit_detail	0	0
Location	0	NA
Cost	0	NA
Care_site	0	NA
Note	0	0
Payer_plan_period	0	0
Provider	0	NA




historical paper records collected during the long-standing activity of the Modena Oncology Center.

Discussion

At our center, clinical data were collected on paper until 2002. Given the increasing complexity of oncology care and the growing volume of clinical information required for routine

documentation, a gradual transition from paper medical records to an electronic chart (e-chart) was implemented. Supported by the EHDEN project, clinical information has been progressively migrated to the electronic platform over the last 20 years. However, data completeness and consistency were partially compromised by the heterogeneity of legacy systems and by the challenges inherent in repeated migrations.

The evolution of the clinical context, the type of information collected, and its organization required several updates of the



initial mapping design and ETL scripts. In particular, additional staging and normalization layers were introduced between the source systems and the OMOP target tables to resolve inconsistencies across historical datasets and improve traceability. While these intermediate layers improved data coherence, they increased the complexity of the ETL pipeline and required additional development and validation time. The expansion of the data sources also led to substantial revisions of the SQL scripts used in the ETL process and extensions of the concept mapping.

In the updated dataset, multiple inconsistencies were identified, primarily related to missing or implausible dates (e.g., missing diagnosis dates, missing dates of information entry, or inconsistencies in therapy start/end timelines). Additional inconsistencies were observed in drug administration documentation, particularly regarding the number of therapeutic cycles and the longitudinal reconstruction of treatment exposure. Data cleansing activities and clarifications obtained from the source systems allowed improvements in the reconstruction of therapy duration and patient clinical history, achieving the best possible result from the available dataset.

Given the increasing relevance of biological and molecular characteristics in precision oncology, we aimed to collect and harmonize the clinical data of all patients treated at our center and transform them into a standardized structured data model through OMOP-CDM. This approach supports the secondary use of these data for research and quality improvement in clinical practice.

In terms of lessons learned, our experience highlights the importance of iterative source data profiling, traceability across historical migrations, and systematic plausibility checks on temporal variables and longitudinal treatment timelines.

Converting data derived from EHRs into OMOP-CDM can enhance health data governance by enabling standardized reuse of routinely collected clinical data for both healthcare and research purposes (13, 14). The adoption of EHRs has improved access to integrated clinical information and enabled the extraction of large volumes of data to evaluate clinical activity and support quality improvement initiatives. However, secondary use of EHR data for research is frequently limited by data quality issues and heterogeneous documentation practices (15, 16). Data quality harmonization represents a key step in improving the reliability of EHR-derived datasets (6).

As suggested by Weiskopf and Weng, EHR-derived data intended for secondary use require systematic quality assessment methodologies tailored to the research task (7). Core quality dimensions include completeness, correctness, plausibility, concordance, and currency. In our experience, the analysis of the COMNet dataset confirmed incompleteness, inconsistent and implausible data, and missing information. The temporal trends observed in the harmonized dataset also reflect progressive digitization over the last two decades, with increasing documentation of systemic therapies and instrumental controls after 2010, and with limited visit information in earlier years, consistent with changes in documentation workflows and EHR adoption over time.

Further use of routinely collected clinical data will be essential to expand research activities in academic centers. However, unmet needs remain, particularly the lack of dedicated research infrastructure to support sustainable data extraction, quality control, and reuse (16). The availability of high-quality RWD represents a fundamental prerequisite for generating real-world evidence (RWE) on the effectiveness and safety of medical products, including long-term outcomes and adverse events, and

for evaluating complex procedures in settings where randomized clinical trials are not available (1, 4).

Conclusion

This study describes the process of harmonizing routinely collected oncology data from our local EHR sources (COMNet) into the OMOP Common Data Model, to obtain a standardized dataset that can be used as RWD for future observational research. The resulting database represents a structured resource that can support analyses of routine clinical practice and may facilitate participation in collaborative network studies based on a common data model (17–20).

The work was supported by the EHDEN, a European initiative that promotes OMOP-CDM adoption across institutions to enable federated observational research (8). Our experience confirms that the progressive transition from paper records to electronic documentation—together with repeated historical migrations between different systems—can significantly affect data completeness and consistency. Iterative refinement of the ETL process and systematic data quality assessment are therefore essential steps to obtain the best possible result from the available clinical datasets and maximize the research value of EHR-derived oncology data.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval was granted by the Local Ethics Committee (Comitato Etico dell'Area Vasta Emilia Nord, nr 180/2022, 23rd November 2023). Written informed consent was obtained from the participants for participation in the study.

Author contributions

LM: Writing – original draft, Writing – review & editing. EC: Formal analysis, Software, Validation, Writing – original draft. EP: Writing – review & editing. AS: Writing – review & editing. FB: Writing – review & editing. RF: Writing – review & editing. MO: Writing – review & editing. LD: Writing – review & editing. MC: Writing – review & editing. RD: Writing – review & editing. KDE: Writing – review & editing. FG: Writing –

review & editing. AF: Writing – review & editing. FP: Writing – review & editing. RS: Writing – review & editing. MD: Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the EHDEN European Health Data and Evidence Network (no. 806968).

Acknowledgments

We acknowledge the contribution of the EHDEN consortium and the IT and Telematics Technologies Service of the University Hospital of Modena for their technical support in data harmonization.

Conflict of interest

LM reports consultancy and honoraria from Pfizer, Eli Lilly, Roche, Gilead, Novartis, Istituto Gentili, and Daiichi Sankyo, outside the submitted work. FG, AS, RS, FP, and FB report speaker/advisory roles as described in the title page.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Di Maio M, Perrone F, Conte P. Real-world evidence in oncology: opportunities and limitations. *Oncologist*. (2020) 25(5):e746–52. doi: 10.1634/theoncologist.2019-0647
- Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? *N Engl J Med*. (2016) 375(23):2293–7. doi: 10.1056/NEJMs1609216

3. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. *JAMA Netw Open*. (2019) 2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535
4. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer*. (2017) 17(2):79–92. doi: 10.1038/nrc.2016.126
5. Hripscak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. *Stud Health Technol Inform*. (2015) 216:574–8.
6. OHDSI (Observational Health Data Sciences and Informatics). The book of OHDSI (2019). Available online at: <https://ohdsi.github.io/TheBookOfOhdsi/> (Accessed February 17, 2026).
7. Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. *J Am Med Inform Assoc*. (2013) 20(1):144–51. doi: 10.1136/amiajnl-2011-000681
8. Voss EA, Blacketer C, van Sandijk S, Moinat M, Kallfelz M, van Speybroeck M, et al. European Health Data & Evidence Network—learnings from building out a standardized international health data network. *J Am Med Inform Assoc*. (2023) 31(1):209–19. doi: 10.1093/jamia/ocad214
9. Hripscak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. *Proc Natl Acad Sci U S A*. (2016) 113(27):7329–36. doi: 10.1073/pnas.1510502113
10. Reisinger SJ, Ryan PB, O'Hara DJ, Powell GE, Painter JL, Pattishall EN, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. *J Am Med Inform Assoc*. (2010) 17(6):652–62. doi: 10.1136/jamia.2009.002477
11. Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. *eGEMS*. (2017) 4(1):18. doi: 10.13063/2327-9214.1244
12. Voss EA, Makadia R, Matcho A, Ma Q, Knollmann D, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. *J Am Med Inform Assoc*. (2015) 22(3):553–64. doi: 10.1093/jamia/ocu023
13. Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al. Toward a national framework for the secondary use of health data: an American Medical Informatics Association White Paper. *J Am Med Inform Assoc*. (2007) 14(1):1–9. doi: 10.1197/jamia.M2273
14. Weiner MG, Embi PJ. Toward reuse of clinical data for research and quality improvement: the end of the beginning? *Ann Intern Med*. (2009) 151(5):359–60. doi: 10.7326/0003-4819-151-5-200909010-00141
15. Burnum JF. The misinformation era: the fall of the medical record. *Ann Intern Med*. (1989) 110(6):482–4. doi: 10.7326/0003-4819-110-6-482
16. Danciu I, Cowan JD, Basford M, Wang X, Saip A, Osgood S, et al. Secondary use of clinical data: the Vanderbilt approach. *J Biomed Inform*. (2014) 52:28–35. doi: 10.1016/j.jbi.2014.02.003
17. Schuemie MJ, Ryan PB, Pratt N, Chen R, You SC, Krumholz HM, et al. Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND). *J Am Med Inform Assoc*. (2020) 27(8):1331–7. doi: 10.1093/jamia/ocaa103
18. Cimino JJ, Ayres EJ. The clinical research data repository of the US national institutes of health. *Stud Health Technol Inform*. (2010) 160(Pt 2):1299–303. doi: 10.1093/jamia/ocad010
19. Wang Z, Talburt J, Wu N, Dagtas S, Zozus MN. A framework for data quality assessment in clinical research datasets. In: *AMIA Annual Symposium Proceedings* (2017). p. 1671–80.
20. Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. Data quality dashboard: a tool for the assessment of data quality in observational health data. *J Am Med Inform Assoc*. (2021) 28(8):1755–61.